Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
31/03/2026 14:26
March 31 (Reuters) - Maia Biotechnology Inc MAIA.A: MAIA BIOTECHNOLOGY REPORTS OVERALL SURVIVAL EXCEEDING TWO YEARS FOR EIGHT PATIENTS IN ONGOING PHASE 2 CLINICAL TRIAL IN NON-SMALL CELL LUNG CANCER Source text: ID:nGNX4PyWYD Further company coverage: MAIA.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale